These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 33469328)

  • 1. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes.
    Tarigan TJE; Dwijayanti A; Setyowati S; Louisa M
    Diabetes Metab Syndr Obes; 2021; 14():107-116. PubMed ID: 33469328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.
    Christofides EA; Stankiewicz A; Denham D; Bellido D; Franek E; Nakhle S; Łukaszewicz M; Reed J; Cózar-León V; Kosch C; Karaś P; Fitz-Patrick D; Handelsman Y; Warren M; Hollander P; Huffman D; Raskin P; Oroszlán T; Lillestol M; Ovalle F
    Endocr Pract; 2024 Jun; ():. PubMed ID: 38876181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
    Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
    Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus
    Yan X; Feng C; Lou Y; Zhou Z
    Diabetes Ther; 2022 Jun; 13(6):1161-1174. PubMed ID: 35471721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study.
    Bu S; Zhang X; Zhu H; Shuai Y; Xing X; Yang W;
    Diabetes Ther; 2017 Aug; 8(4):887-898. PubMed ID: 28623551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (Beyond VII): Study Protocol for a Randomized Controlled Trial.
    Ji L; Gao Z; Shi B; Bian R; Yin F; Pang W; Gao H; Cui N
    Adv Ther; 2018 Jun; 35(6):864-874. PubMed ID: 29873004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
    Sun B; Sengupta N; Rao A; Donnelly C; Waichale V; Roy AS; Ramaswamy S; Pathak D; Bowsher RR; Raiter Y; Aubonnet P; Barve A
    BMC Endocr Disord; 2021 Jun; 21(1):129. PubMed ID: 34174848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.
    Shah VN; Al-Karadsheh A; Barnes C; Mandry J; Nakhle S; Wernicke-Panten K; Kramer D; Schmider W; Pierre S; Teichert L; Rotthaeuser B; Mukherjee B; Bailey TS
    J Diabetes Sci Technol; 2024 Feb; ():19322968241232709. PubMed ID: 38420944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)].
    Zďarská DJ; Brož J; Křivská B; Rušavý Z; Kvapil M
    Vnitr Lek; 2014 Sep; 60(9):712-9. PubMed ID: 25294758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus.
    Ilag LL; Deeg MA; Costigan T; Hollander P; Blevins TC; Edelman SV; Konrad RJ; Ortmann RA; Pollom RK; Huster WJ; Zielonka JS; Prince MJ
    Diabetes Obes Metab; 2016 Feb; 18(2):159-68. PubMed ID: 26434665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Observational Study of Insulin Glargine in Type 2 Diabetic Patients with Advanced Chronic Kidney Disease.
    Majumder A; RoyChaudhuri S; Sanyal D
    Cureus; 2019 Nov; 11(11):e6191. PubMed ID: 31890395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC; Rosenstock J; Gerich J;
    Diabetes Care; 2003 Nov; 26(11):3080-6. PubMed ID: 14578243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
    Wiesli P; Schories M
    Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus.
    Hu X; Zhang L; Dong C; Dong Y; Jiang J; Gao W
    Adv Ther; 2019 May; 36(5):1132-1142. PubMed ID: 30900200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.